Literature DB >> 7753066

Bismuth subsalicylate toxicity as a cause of prolonged encephalopathy with myoclonus.

M F Gordon1, R I Abrams, D B Rubin, W B Barr, D D Correa.   

Abstract

Bismuth subsalicylate preparations are over-the-counter products for gastrointestinal complaints. Bismuth toxicity causes delirium, psychosis, ataxia, myoclonus, and seizures and is reversible over several weeks or months, when bismuth intake is stopped. We report a 54-year-old man with a 6-week history of progressive confusion and memory difficulty and a 2-3-week history of involuntary movements and gait impairment. His encephalopathy was further characterized by marked multifocal myoclonic jerks, coarse postural tremors, postural instability, and gait ataxia. He gradually improved. Extensive toxic, metabolic, and infectious workup demonstrated bismuth toxicity. Spinal tap and brain magnetic resonance scan were normal. Electroencephalography showed bihemispheric slowing. As his encephalopathy cleared, he reported using bismuth subsalicylate long term (daily intake of 8 oz). Bismuth levels 5 weeks after cessation of bismuth were elevated and normalized after 12 weeks. He followed a typical course for bismuth toxicity with subacute progressive encephalopathy and gradual recovery. Creutzfeldt-Jakob was strongly considered due to his rapidly progressive encephalopathy, multifocal myoclonus, and ataxia. Due to its rarity, bismuth toxicity is often overlooked. We hope this presentation will increase recognition of bismuth toxicity. We believe more detailed labeling of bismuth products is needed to avoid similar toxicity from this readily available product.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7753066     DOI: 10.1002/mds.870100215

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  9 in total

Review 1.  An understanding of excessive intestinal gas.

Authors:  F L Suarez; M D Levitt
Journal:  Curr Gastroenterol Rep       Date:  2000-10

2.  The syndrome of delayed post-hypoxic leukoencephalopathy.

Authors:  David Shprecher; Lahar Mehta
Journal:  NeuroRehabilitation       Date:  2010       Impact factor: 2.138

3.  Radio-opaque punctate opacities on the chest radiograph following intravenous injection of a bismuth compound.

Authors:  D J Addrizzo-Harris; A Churg; W N Rom
Journal:  Thorax       Date:  1997-03       Impact factor: 9.139

Review 4.  Ataxia.

Authors:  Umar Akbar; Tetsuo Ashizawa
Journal:  Neurol Clin       Date:  2015-02       Impact factor: 3.806

Review 5.  Drug-induced movement disorders.

Authors:  F J Jiménez-Jiménez; P J García-Ruiz; J A Molina
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

6.  Site of bismuth absorption from bismuth subsalicylate: implications for treatment of colonic conditions.

Authors:  F L Suarez; J Furne; J Stiehm; C Garten; M D Levitt
Journal:  Dig Dis Sci       Date:  2000-07       Impact factor: 3.199

Review 7.  Drug-induced myoclonus: frequency, mechanisms and management.

Authors:  Félix Javier Jiménez-Jiménez; Inmaculada Puertas; María de Toledo-Heras
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

8.  Labeling Stem Cells with a New Hybrid Bismuth/Carbon Nanotube Contrast Agent for X-Ray Imaging.

Authors:  Mayra Hernández-Rivera; Stephen Y Cho; Sakineh E Moghaddam; Benjamin Y Cheong; Maria da Graça Cabreira-Hansen; James T Willerson; Emerson C Perin; Lon J Wilson
Journal:  Contrast Media Mol Imaging       Date:  2019-06-11       Impact factor: 3.161

Review 9.  Is There a Role for Bismuth in Diarrhea Management?

Authors:  Helen Senderovich; Megan Vierhout
Journal:  Rambam Maimonides Med J       Date:  2021-01-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.